Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.60 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 1/20 | 0.60 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.60 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.60 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15285417 | 1.00 | FAAH (0.64) | FAAHEPHX1CXCR1CXCR2PTGS2 | |
| (R)-Ibuprophen SCHEMBL3901515 | 0.81 | PTGS1 (0.81) | FAAHEPHX1CXCR1CXCR2PTGS2 | |
| Ibuprofen SCHEMBL6252408 | 0.81 | PTGS1 (0.81) | FAAHEPHX1CXCR1CXCR2PTGS2 | |
| SCHEMBL3886291 | 0.80 | ALOX5 (0.44) | FAAHEPHX1ALOX5TSHRCA2 | |
| SCHEMBL4481658 | 0.80 | FAAH (0.72) | FAAHEPHX1CXCR1CXCR2PTGS2 | |
| SCHEMBL4487227 | 0.80 | FAAH (0.72) | FAAHEPHX1CXCR1CXCR2PTGS2 | |
| SCHEMBL13179861 | 0.80 | FAAH (0.72) | FAAHEPHX1CXCR1CXCR2PTGS2 | |
| SCHEMBL260688 | 0.78 | EPHX1 (1.00) | FAAHEPHX1CXCR1CXCR2PTGS2 | |
| SCHEMBL3152241 | 0.78 | EPHX1 (1.00) | FAAHEPHX1CXCR1CXCR2PTGS2 | |
| SCHEMBL25872277 | 0.78 | CXCR1 (0.70) | FAAHEPHX1CXCR1CXCR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646193-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici S.p.A. (IT) | 2025-11-12 | — | — | EP | claimed |
| US-12268671-B2 | IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2025-04-08 | — | — | US | claimed |
| EP-3700514-B1 | COMBINATION OF IL-8 INHIBITORS AND IL-6/GP-130 INHIBITORS FOR USE IN THE TREATMENT OF LUNG METASTASIS ASSOCIATED TO OSTEOSARCOMA | DOMPE FARM SPA (IT) | 2025-03-19 | — | — | EP | claimed |
| WO-2024146918-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | claimed |
| EP-4301351-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | Dompe' Farmaceutici SpA (IT) | 2024-01-10 | — | — | EP | claimed |
| EP-4240485-A1 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | Icahn School of Medicine at Mount Sinai (US) | 2023-09-13 | — | — | EP | claimed |
| CN-110769824-B | IL-8 inhibitors for the treatment and/or prophylaxis of bacterial secondary infections | 东佩制药股份公司 | 2023-05-23 | — | — | CN | claimed |
| EP-4125848-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici SpA (IT) | 2023-02-08 | — | — | EP | claimed |
| EP-4106739-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF CANCER-RELATED FATIGUE | Dompe' Farmaceutici SpA (IT) | 2022-12-28 | — | — | EP | claimed |
| EP-4106738-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dompe' Farmaceutici SpA (IT) | 2022-12-28 | — | — | EP | claimed |
| CN-115484943-A | Combination of CXCL8 (interleukin-8) activity inhibitor and corticosteroid, pharmaceutical composition and use thereof | 导博药物公司 | 2022-12-16 | — | — | CN | claimed |
| CN-115397404-A | CXCL8 inhibitors for the treatment of COVID-19 | 东佩制药股份公司 | 2022-11-25 | — | — | CN | claimed |
| WO-2022184841-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DOMPE' FARMACEUTICI SPA (IT) | 2022-09-09 | — | — | WO | claimed |
| WO-2022098822-A1 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-05-12 | — | — | WO | claimed |
| CN-108463219-B | IL-8 inhibitors for the treatment of chemotherapy-induced peripheral neuropathy | 东佩制药股份公司 | 2021-09-17 | — | — | CN | claimed |
| EP-3402474-B1 | IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | DOMPE FARM SPA (IT) | 2021-07-21 | — | — | EP | claimed |
| CN-111343973-A | IL-8 inhibitors for the treatment of certain sarcomas | 多姆皮制药公司 | 2020-06-26 | — | — | CN | claimed |
| CN-110769824-A | IL-8 inhibitors for the treatment and/or prevention of bacterial secondary infections | 东佩制药股份公司 | 2020-02-07 | — | — | CN | claimed |
| US-20150065575-A1 | S100A8/A9 as a Diagnostic Marker and a Therapeutic Target | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-03-05 | — | — | US | claimed |
| EP-4646193-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici S.p.A. (IT) | 2025-11-12 | — | — | EP | disclosed |
| EP-4558124-A1 | POWDER MIXTURE COMPRISING REPARIXIN | Dompé farmaceutici SpA (IT) | 2025-05-28 | — | — | EP | disclosed |
| EP-4558123-A1 | REPARIXIN LIQUID SUSPENSIONS | Dompé farmaceutici SpA (IT) | 2025-05-28 | — | — | EP | disclosed |
| CN-119630389-A | Powder mixtures comprising rapamycin | 导博药物公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119604272-A | Repairisin liquid suspension | 导博药物公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2024146918-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | disclosed |
| US-20240148765-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING THERAPY-RELATED CARDIOMYOPATHY ASSOCIATED WITH NEUTROPHIL INFILTRATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-05-09 | — | — | US | disclosed |
| CN-115484943-B | Combination of CXCL8 (interleukin-8) activity inhibitor and corticosteroid, pharmaceutical composition and use thereof | 导博药物公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024017940-A1 | REPARIXIN LIQUID SUSPENSIONS | DOMPE' FARMACEUTICI SPA (IT) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017945-A1 | POWDER MIXTURE COMPRISING REPARIXIN | DOMPE' FARMACEUTICI SPA (IT) | 2024-01-25 | — | — | WO | disclosed |
| EP-4301351-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | Dompe' Farmaceutici SpA (IT) | 2024-01-10 | — | — | EP | disclosed |
| EP-4240485-A1 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | Icahn School of Medicine at Mount Sinai (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-110769824-B | IL-8 inhibitors for the treatment and/or prophylaxis of bacterial secondary infections | 东佩制药股份公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-4125848-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici SpA (IT) | 2023-02-08 | — | — | EP | disclosed |
| EP-4106739-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF CANCER-RELATED FATIGUE | Dompe' Farmaceutici SpA (IT) | 2022-12-28 | — | — | EP | disclosed |
| EP-4106738-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dompe' Farmaceutici SpA (IT) | 2022-12-28 | — | — | EP | disclosed |
| CN-115484943-A | Combination of CXCL8 (interleukin-8) activity inhibitor and corticosteroid, pharmaceutical composition and use thereof | 导博药物公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115397404-A | CXCL8 inhibitors for the treatment of COVID-19 | 东佩制药股份公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2022184841-A1 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DOMPE' FARMACEUTICI SPA (IT) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022098822-A1 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-05-12 | — | — | WO | disclosed |
| CN-108463219-B | IL-8 inhibitors for the treatment of chemotherapy-induced peripheral neuropathy | 东佩制药股份公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-111343973-A | IL-8 inhibitors for the treatment of certain sarcomas | 多姆皮制药公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-110769824-A | IL-8 inhibitors for the treatment and/or prevention of bacterial secondary infections | 东佩制药股份公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-2831593-B1 | S100A8/A9 AS A DIAGNOSTIC MARKER AND A THERAPEUTIC TARGET | SLOAN KETTERING INST CANCER RES (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9493402-B2 | Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| EP-1366018-B1 | OMEGA-AMINOALKYLAMIDES OF (R)-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-06 | — | — | EP | disclosed |
| EP-1590314-B1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2015-08-05 | — | — | EP | disclosed |
| US-20150065575-A1 | S100A8/A9 as a Diagnostic Marker and a Therapeutic Target | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-03-05 | — | — | US | disclosed |
| EP-2831593-A1 | S100A8/A9 AS A DIAGNOSTIC MARKER AND A THERAPEUTIC TARGET | Sloan Kettering Institute For Cancer Research (US) | 2015-02-04 | — | — | EP | disclosed |
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-20140212380-A1 | TARGETS AND AGENTS FOR THE TREATMENT OF IMPAIRED BONE FRACTURE HEALING | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2014-07-31 | — | — | US | disclosed |
| EP-2718728-A1 | TARGETS AND AGENTS FOR THE TREATMENT OF IMPAIRED BONE FRACTURE HEALING | Université Libre de Bruxelles (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| WO-2013148370-A1 | S100A8/A9 AS A DIAGNOSTIC MARKER AND A THERAPEUTIC TARGET | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | Dompé S.p.A. (IT) | 2013-03-28 | — | — | US | disclosed |
| WO-2012168484-A1 | TARGETS AND AGENTS FOR THE TREATMENT OF IMPAIRED BONE FRACTURE HEALING | Université Libre de Bruxelles (BE) | 2012-12-13 | — | — | WO | disclosed |
| US-8288368-B2 | inhibitors of the C5a induced chemotaxis; psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion | DOMPÉ PHA.R.MA S.P.A. (IT) | 2012-10-16 | — | — | US | disclosed |
| US-20110195967-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2011-08-11 | — | — | US | disclosed |
| US-20100267726-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-10-21 | — | — | US | disclosed |
| US-7776909-B2 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPE PHA.R.MA S.P.A. (IT) | 2010-08-17 | — | — | US | disclosed |
| EP-2066335-A1 | CYTOKINE SIGNALING | Case Western Reserve University (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1844001-B1 | METABOLITES OF 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-06-10 | — | — | EP | disclosed |
| US-20090131441-A1 | Metabolites Of 2-Arylpropionic Acid Derivatives And Pharmaceutical Compositions Containing Them | DOMPE PHAR.R.MA S.P.A. (IT) | 2009-05-21 | — | — | US | disclosed |
| US-20090041753-A1 | Cytokine signaling | CASE WESTERN RESERVE UNIVERSITY | 2009-02-12 | — | — | US | disclosed |
| WO-2008039876-A1 | CYTOKINE SIGNALING | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPE PHA.R.MA S.P.A. (IT) | 2008-02-21 | — | — | US | disclosed |
| EP-1844001-A1 | METABOLITES OF 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2007-10-17 | — | — | EP | disclosed |
| EP-1276732-B1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | DOMPE PHA R MA SPA RES & MFG (IT) | 2007-09-26 | — | — | EP | disclosed |
| US-7217707-B2 | Amide of R-2-(aminoaryl)-propionic acid for use in the prevention of leucocyte activation | DOMPE S.P.A. (IT) | 2007-05-15 | — | — | US | disclosed |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2006-10-05 | — | — | US | disclosed |
| WO-2006079624-A1 | METABOLITES OF 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2006-08-03 | — | — | WO | disclosed |
| EP-1590314-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompe' S.P.A. (IT) | 2005-11-02 | — | — | EP | disclosed |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPE S.P A. (IT) | 2005-04-14 | — | — | US | disclosed |
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-23 | — | — | US | disclosed |
| WO-2004069782-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2004-08-19 | — | — | WO | disclosed |
| EP-1366018-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.P.A. (IT) | 2003-12-03 | — | — | EP | disclosed |
| EP-1276732-A1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | Dompé S.P.A. (IT) | 2003-01-22 | — | — | EP | disclosed |
| WO-2002068377-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.p.A. (IT) | 2002-09-06 | — | — | WO | disclosed |
| WO-2001079189-A2 | 'AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION' | Dompé S.p.A. (IT) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079189-A2 | 'AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION' | Dompé S.p.A. (IT) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12268671-B2 | IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy | CXCL8, CCR8, CXCR1 | FAAH 1186/4885EPHX1 858/4885CXCR1 3/4885 |
| US-20100267726-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, MMP8, CXCR1 | FAAH 345/4885EPHX1 1313/4885CXCR1 3/4885 |
| US-20110195967-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, MMP8, CXCR1 | FAAH 348/4885EPHX1 1309/4885CXCR1 3/4885 |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | C5AR2, C3AR1, C5AR1 | FAAH 174/4885EPHX1 1121/4885CXCR1 461/4885 |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | CXCR2, CXCR1, MMP8 | FAAH 641/4885EPHX1 2088/4885CXCR1 2/4885 |
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | MMP8, CXCL8, HCAR2 | FAAH 330/4885EPHX1 1236/4885CXCR1 384/4885 |
| US-20090131441-A1 | Metabolites Of 2-Arylpropionic Acid Derivatives And Pharmaceutical Compositions Containing Them | CXCR2, CXCR3, MMP8 | FAAH 586/4885EPHX1 831/4885CXCR1 4/4885 |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | C5AR2, C3AR1, C5AR1 | FAAH 239/4885EPHX1 1052/4885CXCR1 798/4885 |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | C5AR2, C3AR1, C5AR1 | FAAH 197/4885EPHX1 946/4885CXCR1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.